Gufic Biosciences Limited (GUFICBIO.BO)
- Previous Close
307.90 - Open
307.40 - Bid 311.75 x --
- Ask 312.50 x --
- Day's Range
306.90 - 313.05 - 52 Week Range
192.00 - 364.00 - Volume
3,164 - Avg. Volume
9,495 - Market Cap (intraday)
31.207B - Beta (5Y Monthly) --
- PE Ratio (TTM)
35.61 - EPS (TTM)
8.74 - Earnings Date Aug 9, 2024 - Aug 13, 2024
- Forward Dividend & Yield 0.10 (0.03%)
- Ex-Dividend Date Sep 21, 2023
- 1y Target Est
--
Gufic Biosciences Limited manufactures and markets active pharmaceutical ingredients (APIs), generic pharmaceuticals, and related services in India, Africa, Asia, Europe, Australia, North America, South America, and internationally. The company manufactures APIs and bulk drugs, such as antifungals, anesthetics, immuno suppressants, and intermediates for antifungals. It manufactures lyophilized injections, which include antibiotic, antifungal, cardiac, infertility, antiviral, and proton-pump inhibitor segments. In addition, the company offers spark, criti care, criticare life, and ferticare pharmaceutical products; and herbal, aesthaderm, gufic stridden, and personal care products. It supplies its products to hospital chains and medical facilities. Gufic Biosciences Limited was founded in 1970 and is based in Mumbai, India.
www.gufic.com--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: GUFICBIO.BO
Performance Overview: GUFICBIO.BO
Trailing total returns as of 6/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GUFICBIO.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GUFICBIO.BO
Valuation Measures
Market Cap
30.88B
Enterprise Value
34.07B
Trailing P/E
35.23
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.76
Price/Book (mrq)
5.80
Enterprise Value/Revenue
4.22
Enterprise Value/EBITDA
23.01
Financial Highlights
Profitability and Income Statement
Profit Margin
10.65%
Return on Assets (ttm)
8.38%
Return on Equity (ttm)
19.57%
Revenue (ttm)
8.09B
Net Income Avi to Common (ttm)
861.36M
Diluted EPS (ttm)
8.74
Balance Sheet and Cash Flow
Total Cash (mrq)
134.84M
Total Debt/Equity (mrq)
62.51%
Levered Free Cash Flow (ttm)
-1.31B